ArticleiGIE : innovation, investigation and insights2025
An affixed, ingestible blood-sensing monitor for continuous monitoring after high-risk endoscopic procedures: a case series.
Article in iGIE : innovation, investigation and insights, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Detecting postprocedural bleeding (PPB) after high-risk endoscopic interventions remains challenging. A fixed intraluminal bleeding sensor could improve PPB detection. Methods: This case series included patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) who were monitored for 24 to 48 hours by affixing a capsule-based bleeding sensor to the duodenal wall. Results: Five patients underwent ERCP with sphincterotomy (n = 3) or ampullectomy (n = 2). The sensor was positive in 3 and negative in 2. Repeat endoscopy confirmed bleeding in 2 sensor-positive cases and 1 sensor-negative case, and hemostasis was successfully achieved. Sensor migration occurred in 3 cases. One patient with persistently negative readings was safely discharged. No adverse events occurred over 3 to 6 months of follow-up. Conclusions: This pilot series supports the feasibility of a fixed capsule-based sensor for real-time PPB detection as an adjunct to standard monitoring. Larger studies are needed to validate effectiveness and optimize deployment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.